Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 156 Show results per page	View Search Criteria \| Help With Results


1.		Toxicity/Benefit Ratio Optimization of Chemotherapy in Colorectal Cancer (CRC) Patients by Determination of Individual Genotypic Determinants

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Diagnostic, Treatment				Active				18 to 85				Other				COLOGEN NCT00138060

First Published: 11/14/2007


2.		Phase IV Study of Chemoresistance Markers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Biomarker/Laboratory analysis, Treatment				Active				18 and over				Other				CHUL-BIO-COLON RECF0356, INCA-RECF0356, NCT00559676

Last Modified: 6/15/2007 First Published: 5/23/2005


3.		Phase II/III Randomized Study of Oxaliplatin, Irinotecan, Leucovorin Calcium, and Fluorouracil Versus Gemcitabine as First-Line Chemotherapy in Patients With Metastatic Adenocarcinoma of the Pancreas

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 to 75				Other				FRE-FNCLCC-ACCORD-11/0402 EU-20512, NCT00112658


4.		A Study for Small Cell Lung Cancer (SCLC) in Extensive Disease Stage

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 to 75				Other				Haema CBF SCLC UK/AS 01 NCT00168896


5.		Second Line Chemotherapy for S-1 Refractory Advanced Gastric Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				20 and over				Other				JACCRO GC-05 NCT00639327

Last Modified: 1/14/2009 First Published: 2/20/2004


6.		Phase III Randomized Study of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) With or Without Cetuximab (C225) After Curative Resection for Patients with Stage III Colon Cancer (Note: All Treatment Arms Containing Irinotecan Closed to Accrual as of 6/1/2005)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 69				NCI				NCCTG-N0147 ECOG-N0147, N0147, NCT00079274


7.		Trial Comparing Two Strategies of Chemotherapy for Metastatic Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				75 and under				Other				FFCD 2000 – 05 CET 815, NCT00126256


8.		5FU/VL Vs LV5FU2 + CPT11 in Stage II-III Resected Rectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Over 18				Other				AERO-R98 NCT00189657

Last Modified: 5/7/2007 First Published: 12/16/2005


9.		Phase III Randomized Study of Oxaliplatin, Fluorouracil, and Leucovorin Calcium (FOLFOX 4) Versus High-Dose Oxaliplatin, Fluorouracil, and Leucovorin Calcium (FOLFOX 7) Followed by Irinotecan Hydrochloride, Fluorouracil, and Leucovorin Calcium (FOLFIRI) in Patients With Colorectal Cancer Metastatic to the Liver

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 75				Other, Pharmaceutical / Industry				GERCOR-C02-1 GERCOR-C02-1-MIROX, EU-20567, SANOFI-GERCOR-C02-1, NCT00268398

Last Modified: 1/14/2009 First Published: 12/9/2005


10.		Phase III Randomized Study of Cetuximab and/or Bevacizumab in Combination With Either Oxaliplatin, Fluorouracil, and Leucovorin Calcium (FOLFOX) OR Irinotecan Hydrochloride, Fluorouracil, and Leucovorin Calcium (FOLFIRI) in Patients With Previously Untreated Metastatic Adenocarcinoma of the Colon or Rectum

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				CALGB-C80405 C80405, SWOG-C80405, NCT00265850

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute